Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups.

Background/Objectives: Elevated lipoprotein(a) [Lp(a)] is associated with increased incidence of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the utility of Lp(a) as an ASCVD risk-enhancing factor, as recommended by the 2019 ACC/AHA guidelines on ASCVD primary prevention, and t...

Descripción completa

Detalles Bibliográficos
Publicado en:Nutrients Vol. 17; no. 8; pp. 1324 - 1343
Autores principales: Hoogeveen, Ron C., Diffenderfer, Margaret R., Lim, Elise, Liu, Ching-Ti, Ikezaki, Hiroaki, Guan, Weihua, Tsai, Michael Y., Ballantyne, Christie M.
Formato: research tables/charts Journal Article
Publicado: MDPI Apr2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184755549&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 184755549
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20726643
        B0TT
      jtl: Nutrients
      issn: 20726643
      maglogo: N
    pubinfo:
      dt: Apr2025
      vid: 17
      iid: 8
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        184755549
        184755549
        184755549
        10.3390/nu17081324
        184755549
      ppf: 1324
      ppct: 19
      formats:
      tig:
        atl: Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups.
      aug:
        au:
          Hoogeveen, Ron C.
          Diffenderfer, Margaret R.
          Lim, Elise
          Liu, Ching-Ti
          Ikezaki, Hiroaki
          Guan, Weihua
          Tsai, Michael Y.
          Ballantyne, Christie M.
        affil: Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
      sug:
        subj:
          Lipoproteins Blood
          Coronary Arteriosclerosis Risk Factors
          C-Reactive Protein Blood
          Practice Guidelines
          American Heart Association
          Coronary Arteriosclerosis Prevention and Control
          Human
          Male
          Female
          Middle Age
          Aged
          Lipids Blood
          Body Weight
          Body Height
          Comparative Studies
          Descriptive Statistics
          Confidence Intervals
          Odds Ratio
          Funding Source
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background/Objectives: Elevated lipoprotein(a) [Lp(a)] is associated with increased incidence of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the utility of Lp(a) as an ASCVD risk-enhancing factor, as recommended by the 2019 ACC/AHA guidelines on ASCVD primary prevention, and to determine whether C-reactive protein (CRP) modifies the association of elevated Lp(a) with ASCVD risk. Methods: Lp(a), high sensitivity CRP (hs-CRP), and other ASCVD risk factors, including blood lipids, blood pressure, diabetes status, body weight and height, and smoking, were measured in 15,933 participants (median age 61.7 years with 25th–75th percentiles 57–68 years, 56.7% female, 19.7% Black, free of ASCVD at baseline) in the Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis. Participants were followed for 10 years for incident ASCVD (coronary heart disease (CHD) or stroke) and CHD (including angioplasty and/or coronary artery bypass but minus stroke). These endpoints occurred in 9.7% and 7.4% of subjects, respectively. Results: Compared with the lowest Lp(a) category (<10 mg/dL), the highest Lp(a) category (≥50 mg/dL) carried a significantly increased incidence of ASCVD (hazard ratio [HR] = 1.31; 95% confidence interval [CI] 1.15–1.50; p < 0.001) and CHD (HR = 1.49; 95%CI 1.27–1.75; p < 0.001). The association of elevated Lp(a) with incident ASCVD was stronger in males and non-Black individuals and was independent of diabetes status. Lp(a) levels ≥ 50 mg/dL predicted the 10-year ASCVD risk for those at intermediate risk (≥7.5%, HR = 1.32; 95%CI 1.15–1.52; p < 0.001). There was a significant interaction between Lp(a) and hs-CRP; individuals with concomitant elevated levels of Lp(a) and hs-CRP had the highest ASCVD risk. Conclusions: Elevated Lp(a) levels were associated with increased ASCVD risk, particularly in individuals with concomitantly elevated hs-CRP levels and those at intermediate 10-year ASCVD risk.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N